BRTX Stock, BioRestorative Therapies Inc Information

We develop therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs are: Disc/Spine Program brtxDISCTM : Our lead cell therapy candidate, BRTX , is a product formulated from autologous cultured mesenchymal stem cells collected from bone marrow. We intend that the product will be used for the non surgical treatment of protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. The treatment is intended for patients whose pain has not been alleviated by non invasive procedures and who potentially face the prospect of surgery. We have received clearance from the Food and Drug Administration to commence a Phase clinical trial using BRTX to treat chronic lower back pain due to degenerative disc disease related to protruding/bulging discs. Metabolic Program ThermoStem : We are developing a cell based therapy to target obesity and metabolic disorders using brown adipose fat derived stem cells to generate brown adipose tissue BAT . BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.